We unite science, technology and talent to get ahead of disease together.
Getting ahead of disease is one of the greatest, most inspiring challenges there is on the planet. By pursuing this purpose together, we have the scale and expertise to positively impact the health of over 2.5 billion people in the next 10 years. In doing so, we will deliver stronger and more sustainable growth as a company where people can thrive.
GSK at a glance
Getting ahead means preventing disease as well as treating it. Globally, our portfolio spans vaccines, specialty and general medicines, with R&D focused on science of the immune system, human genetics and advanced technologies.
- £5.3 billion ($AUD 9.4 billion) R&D investment in 2021
- 20+ deals executed to secure access to novel clinical programs